Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07155226 · ClinicalTrials.gov registry record · Phase 1

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

A Phase 1 study of Higher-risk Myelodysplastic Syndromes and Acute Lymphoblastic Leukaemia, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
84
Enrollment target
20
Study locations

NCT07155226 is a Phase 1 study of Higher-risk Myelodysplastic Syndromes and Acute Lymphoblastic Leukaemia that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 84 participants. The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07155226, a Phase 1 study of Higher-risk Myelodysplastic Syndromes and Acute Lymphoblastic Leukaemia, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
84 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.

Conditions Studied

Higher-risk Myelodysplastic Syndromes Acute Lymphoblastic Leukaemia Acute Myeloid Leukaemia

Interventions

  • DRUG AZD3632
  • DRUG Posaconazole

Study Locations (20)

Other

  • Research Site - Fitzroy
  • Research Site - Perth
  • Research Site - Copenhagen
  • Research Site - Dresden
  • Research Site - Frankfurt A. Main
  • Research Site - Halle
  • Research Site - Heidelberg
  • Research Site - München
  • Research Site - Ulm
  • Research Site - Bologna
  • Research Site - Ravenna
  • Research Site - Bunkyō City
  • Research Site - Kashiwa

Illinois

  • Research Site - Decatur

New York

  • Research Site - New York

North Carolina

  • Research Site - Durham

Oregon

  • Research Site - Portland

Texas

  • Research Site - Houston

Ontario

  • Research Site - Toronto

Quebec

  • Research Site - Montreal

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2026-01-09
Est. Completion 2029-02-15
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07155226

The ClinicalTrials.gov registry entry for NCT07155226 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Higher-risk Myelodysplastic Syndromes appearing as the primary indexed condition, and to 2 interventions - of which AZD3632 is the first listed.

NCT07155226 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Illinois, New York.

Frequently Asked Questions

What is clinical trial NCT07155226 about?

NCT07155226 is a clinical study titled "Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression". The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (...

What is the current status of trial NCT07155226?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2026-01-09. Estimated completion is 2029-02-15.

What conditions does trial NCT07155226 study?

This clinical trial studies the following conditions: Higher-risk Myelodysplastic Syndromes, Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia.

What interventions are being tested in trial NCT07155226?

The interventions under investigation include: AZD3632 (DRUG), Posaconazole (DRUG).

Who is sponsoring clinical trial NCT07155226?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07155226 being conducted?

This trial has 20 study locations across Illinois, New York, North Carolina, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Higher-risk Myelodysplastic Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Higher-risk Myelodysplastic Syndromes

All registered trials for this condition

Acute Lymphoblastic Leukaemia

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.